Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Monitoring therapeutic efficacy of sunitinib using [18F]FDG and [18F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma

Fig. 3

Biomarker quantification by digital microscopy. Each column corresponds to a labelling: a CD31, b HIF1 alpha, c TUNEL, d Ki-67, e F4/80, f GLUT1. Representative control and 9 day-treated tissues are displayed on first and second rows respectively. The third row presents the associated values. In bright field images, the biomarker of interest is labelled in brown and nuclei are counterstained in blue. In fluorescence images, TUNEL labelling is represented in green and nuclei are counterstained in blue

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us